We set a target candidate profile (TCP) objective with affinity, lipophilicity, and solubility goals (Table 1, Figure 4A) for a hypothetical hit-to-lead phase of a discovery program against ABL1, a kinase dysregulated in cancers such as chronic myelogenous leukemia [77]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.